Video Experimental Relacionado
Updated: Aug 12, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Los polimorfismos de la glicoproteína IIIa de las plaquetas y el riesgo de trombosis de stent coronario
D H Walter1, V Schächinger, M Elsner
1Department of Internal Medicine IV, University of Frankfurt, Germany.
Lancet (London, England)
|July 4, 1998
Resumen
La variante del gen PIA2 aumenta el riesgo de trombosis del stent coronario. Este hallazgo sugiere que la terapia antiplaquetaria personalizada puede ser beneficiosa para los pacientes con este marcador genético.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Genética La genética.
- Investigación de la trombosis.
Sus antecedentes:
- Los stents coronarios tratan eficazmente las estenosis coronarias, pero conllevan el riesgo de trombosis del stent.
- La agregación plaquetaria es un factor crítico en el desarrollo de la trombosis del stent.
- El estudio investiga la asociación entre un polimorfismo genético específico de la glicoproteína IIIa plaquetaria (PIA2) y el riesgo de trombosis de stent coronario.
Objetivo del estudio:
- Para determinar si el alelo PIA2 del gen de la glicoproteína IIIa plaquetaria está asociado con un mayor riesgo de trombosis del stent coronario.
- Para identificar los predictores genéticos de la trombosis de stent en pacientes sometidos a la inserción de stent coronario.
Principales métodos:
- Un estudio prospectivo siguió a 318 pacientes durante 30 días después de la inserción de un stent coronario.
- La reacción en cadena de la polimerasa (PCR) y la electroforesis en gel se utilizaron para identificar los alelos PIA1 y PIA2.
- El análisis de regresión logística calculó la relación de probabilidades para la oclusión de stent, evaluando el riesgo relativo asociado con el alelo PIA2.
Principales resultados:
- El alelo PIA2 estaba presente en el 19,8% de los pacientes; el 80,2% eran homocigotos para PIA1.
- La oclusión del stent vascular se produjo en el 9,5% de los pacientes con el alelo PIA2 frente al 1,9% de los pacientes homocigotos PIA1.
- El análisis multivariado identificó el genotipo PIA1 / A2 como el único predictor independiente significativo de la trombosis de stent (Ratio de probabilidades 5.26).
Conclusiones:
- Los pacientes portadores del alelo PIA2 se enfrentan a un riesgo significativamente mayor de trombosis de stent coronario.
- Esta predisposición genética puede guiar el uso de inhibidores de la glicoproteína IIb/IIIa para la terapia antiplaquetaria.
- Debe considerarse el aumento potencial de las complicaciones hemorrágicas con los inhibidores de la glicoproteína-IIb/IIIa.
Videos de Conceptos Relacionados
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...